Fluticasone Propionate And Salmeterol Powder
Product Images NDC 0527-6010

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 0527-6010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fluticasone Propionate And Salmeterol Inhalation P 1)

Chemical structure of fluticasone propionate, one of the active ingredients in the Fluticasone Propionate and Salmeterol inhalation powder product.*

FDA Label Image

Figure C (Fluticasone Propionate And Salmeterol Inhalation P 10)

An instructional black and white illustration showing a person holding a respiratory inhaler device in their hand. The thumb is placed on one side and fingers grip the other side, with a white arrow indicating the direction to hold or operate the inhaler.*

FDA Label Image

Figure D (Fluticasone Propionate And Salmeterol Inhalation P 11)

Black-and-white photograph of a woman demonstrating the use of a respiratory inhalation device. She is holding the device near her mouth and appears to be exhaling or preparing to inhale the medication powder. The image depicts a step in using an inhaler for respiratory treatment.*

FDA Label Image

Figure E (Fluticasone Propionate And Salmeterol Inhalation P 12)

Black and white image of a woman using a dry powder inhaler by placing it into her mouth and preparing to inhale the powder medication, demonstrating the respiratory administration route of a powdered inhalation drug.*

FDA Label Image

Figure F (Fluticasone Propionate And Salmeterol Inhalation P 13)

Illustration showing hands holding a respiratory inhalation device for powder medication, demonstrating a step where a slider or lever is moved in the direction of a large left-pointing arrow. The image likely indicates part of the device’s preparation or dosing mechanism for Fluticasone Propionate and Salmeterol powder inhalation.*

FDA Label Image

Figure G (Fluticasone Propionate And Salmeterol Inhalation P 14)

An illustration shows a woman holding a glass of water near a kitchen sink while spitting out multiple toothbrushes. This instructional image appears unrelated to any pharmaceutical product or medication use.*

FDA Label Image

Figure H (Fluticasone Propionate And Salmeterol Inhalation P 15)

Fluticasone Propionate and Salmeterol 100 mcg/50 mcg inhalation powder device by Lannett Company, Inc., shown with 60 blisters. The image includes a close-up view of a single blister marked with the number '5'.*

FDA Label Image

100 Mcg Carton (Fluticasone Propionate And Salmeterol Inhalation P 16)

Packaging label for Fluticasone Propionate and Salmeterol Inhalation Powder, USP 100 mcg/50 mcg. The label shows a white inhalation device with purple accents, designed to contain one foil strip of 60 blisters. The product is for oral inhalation only and is labeled as prescription only. The labeler is Lannett Company, Inc., with a logo for Respirent also visible.*

FDA Label Image

250 Carton (Fluticasone Propionate And Salmeterol Inhalation P 17)

Fluticasone Propionate and Salmeterol Inhalation Powder USP 250 mcg/50 mcg powder dosage form for respiratory inhalation. The image shows an inhalation device with a white body and purple mouthpiece. The label indicates it contains 1 inhalation device with 1 foil strip of 60 blisters. Manufactured by Lannett Company, Inc., the product is identified for oral inhalation use only.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fluticasone Propionate And Salmeterol Inhalation P 2)

Chemical structure of fluticasone propionate and salmeterol, the active ingredients in the human prescription drug labeled by Lannett Company, Inc. The image shows molecular formulas representing these compounds.*

FDA Label Image

Figure 1 (Fluticasone Propionate And Salmeterol Inhalation P 3)

A line graph showing percent change in FEV1 over 12 weeks for four groups: Fluticasone Propionate and Salmeterol 100 mcg/50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph illustrates respiratory function improvement across these treatments, with data points and sample sizes noted at select weeks and the study endpoint.*

FDA Label Image

Figure 2 (Fluticasone Propionate And Salmeterol Inhalation P 4)

A line graph displaying the percentage change in FEV1 over a 12-hour period on Day 1 baseline for four groups: Fluticasone Propionate and Salmeterol inhalation powder 100 mcg/50 mcg, Salmeterol 50 mcg, Fluticasone Propionate 100 mcg, and Placebo. The x-axis represents hours (0 to 12), and the y-axis shows percent change in FEV1 (0 to 45). The combination treatment shows the highest increase in FEV1, followed by Salmeterol and Fluticasone alone, with Placebo showing minimal change.*

FDA Label Image

Figure 3 (Fluticasone Propionate And Salmeterol Inhalation P 5)

A line graph depicting the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period for four groups: Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, and Placebo. The Y-axis shows percent change, and the X-axis shows hours from 0 to 12, illustrating differences in respiratory function over time.*

FDA Label Image

Figure 4 (Fluticasone Propionate And Salmeterol Inhalation P 6)

A longitudinal line graph depicting the percent change in FEV1 over 24 weeks among subjects receiving Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg, Salmeterol 50 mcg, or placebo. The x-axis shows time in weeks and the y-axis shows percent change in FEV1. The graph includes a legend and subject counts at different time points for each treatment group.*

FDA Label Image

Figure 5 (Fluticasone Propionate And Salmeterol Inhalation P 7)

A line graph depicting percentage change in FEV1 over 24 weeks and at an endpoint for three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250/50 twice daily, Fluticasone Propionate 250 mcg twice daily, and placebo. The graph shows higher improvement in the combination group compared to fluticasone alone and placebo, with sample sizes noted below for each time point.*

FDA Label Image

Figure A (Fluticasone Propionate And Salmeterol Inhalation P 8)

Illustration of a Fluticasone Propionate and Salmeterol inhalation powder device showing key components including the outer case, mouthpiece, lever, counter, and thumb grip. The label on the device indicates a strength of 100 mcg/50 mcg and contains 60 blisters.*

FDA Label Image

Figure B (Fluticasone Propionate And Salmeterol Inhalation P 9)

Instructional diagram showing hands holding a respiratory inhaler device for Fluticasone Propionate and Salmeterol powder. An arrow indicates a motion or step, likely demonstrating how to prepare or use the inhaler.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.